AzTrials
AzTrials

Weight LossPhase 3NCT07104383

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

A Phase 3 study testing VK2735 in people with Weight Loss, run by Viking Therapeutics, Inc. at 127 sites in 2 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Weight Loss
What is being tested?
VK2735
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
1,100 participants
Where
127 sitesin 2 countries
Study dates
23 Jun 2025to 1 Aug 2027
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years of age at the time of signing the informed consent
  • Body mass index (BMI) ≥27 kg/m2
  • Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Type 2 diabetes mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists

Who cannot join

  • History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
  • Self-reported body weight change of 5% or more within 3 months of screening
  • Have a prior or planned surgical treatment for obesity (except for liposuction or abdominoplasty if performed >1 year prior to screening)
  • Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
  • Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 diabetes mellitus (T2DM)
  • Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening
Show all 12Show fewer
  • Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL
  • Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
  • Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
  • History of acute or chronic pancreatitis
  • Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening

Trial locations and contacts

127 sites in 2 countries.

127 sites in 2 countries

United States125 sites

  • Viking Clinical Site #2047

    Abilene, Texas, 79606

  • Viking Clinical Site #2088

    Albany, New York, 12205

  • Viking Clinical Site #2029

    Albuquerque, New Mexico, 87109

  • Viking Clinical Site #2098

    Arlington, Virginia, 22205

  • Viking Clinical Site #2116

    Atlanta, Georgia, 30329

  • Viking Clinical Site #2063

    Austin, Texas, 78131

  • Viking Clinical Site #2007

    Austin, Texas, 78705

  • Viking Clinical Site #2118

    Baton Rouge, Louisiana, 70808

  • Viking Clinical Site #2139

    Baton Rouge, Louisiana, 70809

  • Viking Clinical Site #2091

    Bellaire, Texas, 77401

  • Viking Clinical Site #2037

    Birmingham, Alabama, 35235

  • Viking Clinical Site #2064

    Birmingham, Alabama, 35249

  • Viking Clinical Site #2124

    Brownsville, Texas, 78526

  • Viking Clinical Site #2010

    Butte, Montana, 59701

  • Viking Clinical Site #2005

    Chandler, Arizona, 85210

  • Viking Clinical Site #2141

    Charlotte, North Carolina, 28205

  • Viking Clinical Site #2094

    Chevy Chase, Maryland, 20815

  • Viking Clinical Site #2006

    Chicago, Illinois, 60607

  • Viking Clinical Site #2071

    Chula Vista, California, 91911

  • Viking Clinical Site #2043

    Cincinnati, Ohio, 45219

  • Viking Clinical Site #2074

    Cincinnati, Ohio, 45242

  • Viking Clinical Site #2031

    City of Saint Peters, Missouri, 63303

  • Viking Clinical Site #2013

    Clearwater, Florida, 33756

  • Viking Clinical Site #2121

    Clearwater, Florida, 33761

  • Viking Clinical Site #2044

    Cleveland, Ohio, 44122

  • Viking Clinical Site #2030

    Columbus, Georgia, 31904

  • Viking Clinical Site #2089

    Columbus, Ohio, 43215

  • Viking Clinical Site #2003

    Cooper City, Florida, 33024

  • Viking Clinical Site #2049

    Dallas, Texas, 75230

  • Viking Clinical Site #2048

    Dallas, Texas, 75235

  • Viking Clinical Site #2148

    Dayton, Ohio, 45420

  • Viking Clinical Site #2112

    DeLand, Florida, 32720

  • Viking Clinical Site #2107

    Delray Beach, Florida, 33445

  • Viking Clinical Site #2119

    Denver, Colorado, 80210

  • Viking Clinical Site #2045

    East Greenwich, Rhode Island, 02818

  • Viking Clinical Site #2070

    Escondido, California, 92025

  • Viking Clinical Site #2027

    Fargo, North Dakota, 58104

  • Viking Clinical Site #2101

    Fayetteville, North Carolina, 28304

  • Viking Clinical Site #2017

    Flagstaff, Arizona, 86001

  • Viking Clinical Site #2083

    Fort Myers, Florida, 33912

  • Viking Clinical Site #2111

    Frisco, Texas, 75033

  • Viking Clinical Site #2026

    Greensboro, North Carolina, 27410

  • Viking Clinical Site #2028

    Greenville, South Carolina, 29607

  • Viking Clinical Site #2140

    Gulfport, Mississippi, 39503

  • Viking Clinical Site #2096

    Hartsdale, New York, 10530

  • Viking Clinical Site #2062

    Honolulu, Hawaii, 96814

  • Viking Clinical Site #2046

    Houston, Texas, 77040

  • Viking Clinical Site #2054

    Huntington Park, California, 90255

  • Viking Clinical Site #2128

    Huntsville, Alabama, 35801

  • Viking Clinical Site #2146

    Indianapolis, Indiana, 46202

  • Viking Clinical Site #2058

    Jacksonville, Florida, 32216

  • Viking Clinical Site #2016

    Kansas City, Missouri, 64131

  • Viking Clinical Site #2004

    Knoxville, Tennessee, 37909

  • Viking Clinical Site #2106

    Lafayette, Louisiana, 70508

  • Viking Clinical Site #2014

    Lake Forest, California, 92630

  • Viking Clinical Site #2076

    Lakeland, Florida, 33803

  • Viking Clinical Site #2060

    Lakewood Rch, Florida, 34211

  • Viking Clinical Site #2077

    Lampasas, Texas, 76550

  • Viking Clinical Site #2035

    Las Vegas, Nevada, 89148

  • Viking Clinical Site #2065

    Lebanon, New Hampshire, 03756

  • Viking Clinical Site #2129

    Lemon Grove, California, 91945

  • Viking Clinical Site #2069

    Lexington, Kentucky, 40509

  • Viking Clinical Site #2040

    Lexington, Kentucky, 40513

  • Viking Clinical Site #2051

    Lincoln, California, 95648

  • Viking Clinical Site #2036

    Little Rock, Arkansas, 72211

  • Viking Clinical Site #2050

    Long Beach, California, 90815

  • Viking Clinical Site #2009

    Louisville, Kentucky, 40213

  • Viking Clinical Site #2078

    Manteca, California, 95336

  • Viking Clinical Site #2095

    Marlton, New Jersey, 08009

  • Viking Clinical Site #2080

    Meridian, Idaho, 83642

  • Viking Clinical Site #2020

    Metairie, Louisiana, 70006

  • Viking Clinical Site #2001

    Methuen, Massachusetts, 01844

  • Viking Clinical Site #2117

    Miami, Florida, 33122

  • Viking Clinical Site #2087

    Monroe, Louisiana, 71201

  • Viking Clinical Site #2053

    Montclair, California, 91763

  • Viking Clinical Site #2110

    Morehead City, North Carolina, 28557

  • Viking Clinical Site #2061

    Morehead City, North Carolina, 28857

  • Viking Clinical Site #2134

    Myrtle Beach, South Carolina, 29572

  • Viking Clinical Site #2008

    Nashville, Tennessee, 37203

  • Viking Clinical Site #2133

    New York, New York, 10036

  • Viking Clinical Site #2113

    Norman, Oklahoma, 73069

  • Viking Clinical Site #2023

    North Charleston, South Carolina, 29405

  • Viking Clinical Site #2012

    Ocoee, Florida, 34761

  • Viking Clinical Site #2002

    Ogden, Utah, 84405

  • Viking Clinical Site #2075

    Omaha, Nebraska, 68134

  • Viking Clinical Site #2056

    Palmetto Bay, Florida, 33157

  • Viking Clinical Site #2068

    Panorama City, California, 91402

  • Viking Clinical Site #2018

    Peoria, Arizona, 85381

  • Viking Clinical Site #2011

    Port Orange, Florida, 32127

  • Viking Clinical Site #2097

    Portland, Oregon, 97202

  • Viking Clinical Site #2126

    Portland, Oregon, 97210

  • Viking Clinical Site #2034

    Reno, Nevada, 89511

  • Viking Clinical Site #2072

    Renton, Washington, 98057

  • Viking Clinical Site #2120

    Rincon, Georgia, 31326

  • Viking Clinical Site #2145

    Rockville, Maryland, 20850

  • Viking Clinical Site #2066

    Rockville, Maryland, 20854

  • Viking Clinical Site #2132

    Rolling Hills Estates, California, 90274

  • Viking Clinical Site #2092

    Salt Lake City, Utah, 84107

  • Viking Clinical Site #2143

    San Antonio, Texas, 78215

  • Viking Clinical Site #2085

    San Antonio, Texas, 78222

  • Viking Clinical Site #2015

    San Antonio, Texas, 78229

  • Viking Clinical Site #2131

    San Diego, California, 92103

  • Viking Clinical Site #2039

    Sandy City, Utah, 84094

  • Viking Clinical Site #2093

    Savannah, Georgia, 31406

  • Viking Clinical Site #2135

    Scottsdale, Arizona, 85260

  • Viking Clinical Site #2102

    Seabrook, Texas, 77586

  • Viking Clinical Site #2147

    Sioux City, Iowa, 68776

  • Viking Clinical Site #2041

    Spokane, Washington, 99218

  • Viking Clinical Site #2052

    Spring Valley, California, 91978

  • Viking Clinical Site #2125

    Springfield, Missouri, 65807

  • Viking Clinical Site #2024

    St. George, Utah, 84790

  • Viking Clinical Site #2082

    Suffolk, Virginia, 23435

  • Viking Clinical Site #2019

    Tucson, Arizona, 85711

  • Viking Clinical Site #2137

    Tulsa, Oklahoma, 74133

  • Viking Clinical Site #2109

    Tustin, California, 92780

  • Viking Clinical Site #2127

    Valparaiso, Indiana, 46383

  • Viking Clinical Site #2067

    Van Nuys, California, 91405

  • Viking Clinical Site #2079

    Walnut Creek, California, 94598

  • Viking Clinical Site #2022

    West Des Moines, Iowa, 50266

  • Viking Clinical Site #2057

    West Palm Beach, Florida, 33407

  • Viking Clinical Site #2032

    Westfield, New York, 14787

  • Viking Clinical Site #2099

    Wichita, Kansas, 67207

  • Viking Clinical Site #2115

    Winston-Salem, North Carolina, 27157

  • Viking Clinical Site #2025

    Woodstock, Georgia, 30189

  • Viking Clinical Site #2038

    Ypsilanti, Michigan, 48197

Other trials in United States

Puerto Rico2 sites

  • Viking Clinical Site #2130

    Mayagüez, 00680

  • Viking Clinical Site #2086

    San Juan, 00927

Other trials in Puerto Rico

About this study

Official title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight

Conditions
Weight Loss
Being tested
VK2735
Medical subject headings
Weight Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VK2735Drug

    VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly

Study groups in NCT07104383
Study groupRoleWhat they receive
Placebo AssignmentPlacebo comparatorVK2735 Placebo Comparator Once Weekly
Receives: Drug: VK2735
Active Assignment (Dose #1)ExperimentalVK2735 7.5mg Once Weekly
Receives: Drug: VK2735
Active Assignment (Dose #2)ExperimentalVK2735 12.5mg Once Weekly
Receives: Drug: VK2735
Active Assignment (Dose #3)ExperimentalVK2735 17.5mg Once Weekly
Receives: Drug: VK2735

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percent change in body weight from baseline to Week 78 in body weight

    Measured: 78 Weeks

Secondary outcomes (1)

  1. Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment

    Measured: 78 Weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Aug 2025
  2. Study start23 Jun 2025
  3. Primary completion1 Jul 2027 (estimated)
  4. Study completion1 Aug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
1,100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07104383
Sponsor's protocol ID
VK2735-302
Status last verified
Apr 2026
First submitted
29 Jul 2025
Last updated
7 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing VK2735 in people with Weight Loss, run by Viking Therapeutics, Inc. at 127 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 127 sites in United States, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent change in body weight from baseline to Week 78 in body weight (time frame: 78 Weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07104383.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in